Rite Aid

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through following segments: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Philadelphia, PA.

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rite Aid is a drugstore chain that offers prescription medications, over-the-counter drugs, and health and wellness products. Rite Aid is reshaping the concept of a modern pharmacy by catering to customer demands through various convenient channels, including retail and delivery pharmacy services. Additionally, the company's offerings extend to services provided by its wholly-owned subsidiaries, namely Elixir, Bartell Drugs, and Health Dialog. Elixir, Rite Aid’s pharmacy benefits and services company, encompasses accredited mail and specialty pharmacies, prescription discount programs, and an advanced adjudication platform. These components combine to provide exceptional member experiences and substantial cost savings. Furthermore, Health Dialog delivers healthcare coaching and disease management services through interactive live online sessions and phone-based health services.

Rite Aid is a health products and services company with 2,400 locations across 17 states.

The company's omnichannel business includes digital, retail, and delivery touchpoints. Rite Aid is a top 20 seller of speciality medications, per its investor website.

In addition to its retail business, Rite Aid owns a pharmacy benefits subdivision (Elixir) and a personalized health services and coaching arm, Health Dialog, which has served 10MM members as of May 2022.

The company has reported $1.85 billion of liquidity with no debt maturities until 2025. According to its investor website, Rite Aid expects to be free cash flow (FCF) positive in FY23.

In Q2 2022, Rite Aid shared a three-part growth strategy aimed at deepening market share, expanding into new markets, and creating new offerings.

To grow the current business, Rite Aid is aiming to increase its e-commerce and digital sales, refresh its loyalty program, and grow its specialty pharmacy offering, which focuses on serving customers with complex health conditions.

New market expansion plans include increasing Rite Aid's footprint of "small format" pharmacies in underserved communities and implementing "store within a store" partnerships.

Rite Aid also aims to grow via new offerings, such as expanded health plan and health system clinical services, a pharmacy benefit manager (PBM) as a service offering, and new strategic partnerships.

Rite Aid Investor Relations

*This is not investment advice.

There's a lot going wrong, and not much going right.

3 Red Flags for Rite Aid's Future

Eaton Vance California Municipal Bond Fund II

Enservco

Barrick Gold

Team

Volt Information Sciences, Inc.

Wondering what you need to do about the possibility of a recession? Learn why Team Inc might be one of your best bets right now.

Recession Fears Are a Golden Opportunity for Deep Value Moonshots

The company's financials aren't great -- but should investors be worried?

Is This Major Pharmacy Retailer in Danger of Going Out of Business?

CVS Health

Walgreens

They're not as great as the arguments in favor might make it seem.

Why These Pharmacy Stocks Aren't a Good Option for Retirement Savings

Rite Aid said Thursday it had rejected a proposal from Spear Point Capital Management to acquire all of its shares.

Rite Aid confirms Post report it rejected Spear Point's $815M buyout offer

After rallying late yesterday on news of a rejected takeover offer, RAD stock is retreating in morning trading today. The post Why Is Rite Aid (RAD) Stock in the Spotlight Today?

Why Is Rite Aid (RAD) Stock in the Spotlight Today?

(Reuters) -Rite Aid Corp said on Thursday it had rejected a proposal from Spear Point Capital Management to acquire all of its shares.

Rite Aid says it rejected Spear Point's buyout offer

Rite Aid Corp. RAD, +10.81% gave further detail on the rejected takeover bid from private-equity firm Spear Point Capital Management, saying that the offer "was not credible and did not warrant further exploration." Spear Point had said it would pay $14.60 for each Rite Aid shares outstanding, according to the New York Post, a a 97.3% premium to Tuesday's closing price of $7.40.

Rite Aid says rejected takeover bid 'was not credible'

PHILADELPHIA--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) confirmed that it previously rejected a non-binding, off-market proposal from Spear Point Capital Management (“Spear Point”) to acquire all of the outstanding shares of the Company's common stock. The Company and its Board of Directors reviewed the proposal with the assistance of its financial and legal advisors, and the Board concluded that the proposal was not credible and did not warrant further exploration. In making its determ

Rite Aid Corporation Confirms Prior Rejection of Non-Binding, Off-Market Proposal from Spear Point Capital Management

Rite Aid Corp (NYSE: RAD) shares closed Wednesday's regular session up more than 11% following a report suggesting the company rejected an $815 million takeover bid earlier this month. According to a New York Post report, citing Spear Point Capital Management co-founder Ron.

What Caused Rite Aid Stock To Spike Today?

Shares of Rite Aid Corp. RAD, +13.78% rocketed as much as 38.5% intraday before paring gains to be up 18.7% in very active afternoon trading Wednesday, after the New York Post reported that the drugstore chain rejected earlier this month a buyout bid that valued the company at more than $800 million. Trading volume swelled to about 16 million share, compared with the full-day average of about 4.3 million shares.

Rite Aid's stock rockets after the New York Post reported it rejected a buyout bid at a hefty premium

Rite Aid earlier this month quietly rejected a takeover bid that valued the drugstore chain at more than $800 million -- despite it being nearly twice the drugstore chain's current stock price, The Post has learned.

Rite Aid rejected $800M takeover bid this month

Drugstore operator Rite Aid Corporation (NYSE: RAD) stock has been pummeled since hitting a post-pandemic high of $32.48 on Jan. 28, 2021.

Rite Aid Stock is Getting Cheap Enough to Buy Here

GlaxoSmithKline

Pfizer

Health care stocks are making the rounds as the pandemic continues to pose challenges globally and high growth names lose steam.

Best Stocks To Buy Right Now? 3 Health Care Stocks In Focus

Rite Aid Corporation (NYSE:RAD ) Q4 2022 Earnings Conference Call April 14, 2022 8:30 AM ET Company Participants Byron Purcell - Investor Relations Heyward Donigan - President & CEO Matt Schroeder - EVP & CFO Andre Persaud - EVP & CRO, Elixir Chris DuPaul - COO, Elixir Conference Call Participants Michael Minchak - JPMorgan Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Jenna Giannelli - Goldman Sachs William Reuter - BofA Securities Karru Martinson - Jefferies Carla Casella - JPMorgan Operator Good morning. My name is Rob, and I will be your conference operator today.

Rite Aid Corporation (RAD) CEO Heyward Donigan on Q4 2022 Results - Earnings Call Transcript

Rite Aid reported a strong close to the 2022 fourth quarter and full year, while also eyeing an outlook in 2023 that leads to the shuttering of 145 stores that have so far proven to be unprofitable. Amid struggles to compete with Walgreens, CVS Health and Walmart pharmacies, Rite Aid is looking to lower costs, […]

Rite Aid Posts Strong Year Amid Shuttering Unprofitable Stores

The company provided a better-than-expected outlook for fiscal 2023.

Why Rite Aid Stock Is Rebounding Today

The shares of Rite Aid Corporation (NYSE:RAD) are surging this morning, last seen up 15.9% to trade at $8.68, after the pharmacy giant reported fiscal fourth-quarter results.

Rite Aid's Sunny Forecast Attracts Options Traders

Rite Aid (RAD) stock is rising higher on Thursday thanks to the company's earnings report for the fourth quarter of fiscal 2022. The post Why Is Rite Aid (RAD) Stock Up 10% Today?

Why Is Rite Aid (RAD) Stock Up 10% Today?

Rite Aid expects to close a total of 145 “unprofitable stores” in ongoing cost-cutting moves designed to help the pharmacy chain be more competitive.

Rite Aid Expects More Closures Of ‘Unprofitable' Stores

Rite Aid Corp (NYSE: RAD) has reported Q4 FY22 sales of 6.06 billion, +2.5% Y/Y, beating the consensus of $5.95 billion. The Company reported an EPS loss of $(1.63) compared to $(0.78) a year ago.

Why Rite Aid Shares Are Soaring Today

Rite Aid Corporation stock (NYSE: RAD) opened more than 15% in premarket trading on Thursday after the pharmacy company reported strong revenue for its fiscal Q4 and gave better than expected guidance for the full year. Key takeaways from Rite Aid Q4 earnings report Net loss printed at $389.1 million versus the year ago figure […] The post Rite Aid stock opens 15% up on Thursday: what happened?

Rite Aid stock opens 15% up on Thursday: what happened?

Rite Aid Corp. RAD, +2.60% shares rose 6.8% in Thursday premarket trading after it reported fourth-quarter revenue that beat consensus and gave guidance ahead of Street expectations. The pharmacy retailer posted a net loss of $389.1 million, or $7.18 per share, after a loss of $18.5 million, or 34 cents per share, last year.

Rite Aid stock jumps after revenue beat and guidance ahead of Street expectations

PHILADELPHIA--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourth quarter and fiscal year ended February 26, 2022. “We exceeded our 2022 plan amid continuing challenges of the COVID-19 pandemic. As we look forward to the year ahead, we are ready and energized to compete in a new post-pandemic normal,” said Heyward Donigan, president and chief executive officer. “We demonstrated the important role that pharmacists play in the everyday health of our c

Rite Aid Corporation Reports Strong Fiscal 2022 Fourth Quarter and Full Year Results and Provides Fiscal 2023 Outlook

Taiwan Semiconductor Manufacturing

UnitedHealth Group

While there were a few interesting earnings reports out Tuesday morning, all eyes were focused on the U.S.

News for Rite Aid Stock (RAD)